902 results on '"Heukamp, Lukas"'
Search Results
2. Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis.
3. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy
4. Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer
5. ALK alterations in salivary gland carcinomas
6. Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
7. Comprehensive genomic profiles of small cell lung cancer
8. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
9. PO009/#424 Innovative academic homologous recombination deficiency tests available in advanced ovarian cancer: the European ENGOT initiative
10. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
11. Molekularpathologie des Lungenkarzinoms: aktuelle Standards und weitere Entwicklungen
12. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
13. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
14. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
15. Synaptopodin-2 Isoforms Have Specific Binding Partners and Display Distinct, Muscle Cell Type-Specific Expression Patterns.
16. Cellular immune responses against the tumour associated polymorphic epithelial mucin MUC1
17. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model
18. Data from CD74–NRG1 Fusions in Lung Adenocarcinoma
19. Data from A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC
20. Data from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
21. Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma
22. Supporting Information from A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC
23. Supplementary Methods and Legends from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
24. Supplementary Table S1 from A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC
25. Supplementary Figures S1-S14 from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
26. Supplementary Figures S1-S10 from A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC
27. Supplementary Figures from CD74–NRG1 Fusions in Lung Adenocarcinoma
28. Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
29. MYCN targets OTX015_BRD4 and gene expression from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
30. Supplementary Figure 2. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
31. Supplemental Table 8 from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
32. Supplementary Figure Legends 1-7 from Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
33. Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
34. Supplementary Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
35. Supplementary Figures 1-7, Table 1 from Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
36. Supplement from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
37. CCR Translation for This Article from Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
38. Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
39. Supplementary Figure 5. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
40. Supplementary Figure Legends from Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
41. Supplementary Figure 2 from SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
42. Supplementary Figure 3 from Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
43. Supplementary Figure 1 from Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
44. Data from Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
45. Data from SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
46. Data from The Prosurvival IKK-Related Kinase IKKϵ Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine
47. Supplementary Figure 2 from Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
48. Supplementary Figure Legend from SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
49. Supplementary Figure 5 from Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer
50. Supplementary Tables 1 - 2 from SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.